Dose calculation of anticancer drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 10, 2008, Pages 1307-1319

  Gao, Bo ^a   Klumpen, Heinz Josef ^a   Gurney, Howard ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b University of Sydney   (Australia)

Author keywords

Anticancer drugs; Body surface area; Dose calculation; Dose cluster; Inter individual variability; Pharmacokinetics; Structured dose revision; Toxicity adjusted dosing

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; KETOCONAZOLE; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; PACLITAXEL; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG; VINCA ALKALOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD TOXICITY; BODY SURFACE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; GENOTYPE; GERM CELL TUMOR; GLOMERULUS FILTRATION RATE; HUMAN; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; OVARY CANCER; PHENOTYPE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GENOTYPE; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 55049115153     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.10.1307     Document Type: Review

References (130)

1. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14(9):2590-611
2. Mathijssen RH, de Jong FA, Loos WJ, et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007;12(8):913-23
3. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005;5(6):447-58
4. Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56(6):1296-302
5. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10(6):995-1000
6. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27(1):23-44
7. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29(7):1338-53
8. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40(6):523-30
9. Wells PG, Mackenzie PI, Chowdhury JR, et al. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 2004;32(3):281-90
10. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-23
11. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991;256(3):1189-94
12. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998;56(6):1019-38
13. Powis G. Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat Rev 1982;9(2):85-124
14. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13(4):566-575
15. Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clin Pharmacokinet 1999;36(6):391-8
16. Wong M, Balleine RL, Blair EY, et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006;24(16):2448-55
17. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57(5):685-92
18. Sonnichsen DS, Liu Q, Schuetz EG, et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995;275(2):566-75
19. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989;16(6):327-36
20. Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997;32(4):324-43
21. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-71
22. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body stuface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978;93(1):62-6
23. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18(7):853-6
24. Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 1993;32(6):411-8
25. Newell DR. Getting the right dose in cancer chemotherapy - time to stop using surface area? Br J Cancer 2002;86(8):1207-8
26. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19(2):171-7
27. Miller AA. Body surface area in dosing anticancer agents: scratch the surface! J Natl Cancer Inst 2002;94(24):1822-3
28. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94(24):1883-8
29. Gurney H, Shaw R. Obesity in dose calculation: a mouse or an elephant? J Clin Oncol 2007;25(30):4703-4
30. Field KMK, Jefford S, Michael M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008;4(3):108-13
31. Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 2007;43(3):544-8
32. Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996;14(11):3000-8
33. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17(4):1105
34. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15(5):1844-52
35. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90(16):1205-11
36. Gurney H, Wong M, Balleine RL, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007;82(1):33-40
37. Li J, Brahmer J, Messersmith W, et al. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 2006;24(4):291-7
38. De Jong FA, Mathijssen RH, Xie R, et al. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004;10(12 Pt 1):4068-71
39. Sharma R, Rivory L, Beale P, et al. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006;94(7):964-8
40. De Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19(17):3733-9
41. Mross K, Hollander N, Frost A, et al. PAC fixed dose: pharmacokinetics of a 1-hoar paclitaxel infusion and comparison to BSA-normalized drug dosing. Onkologie 2006;29(10):444-50
42. Miller AA, Rosner GL, Egorin MJ, et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 2004;10(24):8325-31
43. Smorenburg CH, Sparreboom A, Bontenbal M, et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003;21(2):197-202
44. Loos WJ, de Jongh FE, Sparreboom A, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 2006;24(10):1499-506
45. Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health Syst Pharm 2001;58(18):1760-64
46. Alberts DS, Dorr RT. New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors. Oncologist 1998;3(1):15-34
47. Deeken JF, Figg WD, Bates SE, Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007;18(2):111-26
48. de Jonge ME, Huitema AD, Tukker AC, et al. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 2005;11(1):273-83
49. Millward MJ, Webster LK, Toner GC, et al. Carboplatin dosing based on measurement of renal function - experience at the Peter MacCallum Cancer Institute. Aust N Z J Med 1996;26(3):372-9
50. Miller AA, Tolley EA, Niell HB, et al. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 1992;31(2):161-6
51. Mick R, Ratain MJ. Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 1991;83(21):1560-64
52. Launay-Iliadis MC, Bruno R, Cosson V, et al. Population pharmacokinetics of docetaxel during Phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995;37(1-2):47-54
53. Bruno R, Vivier N, Vergniol JC, et al. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996;24(2):153-72
54. Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994;12(6):1291-95
55. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004;26(2):186-91
56. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45(3):253-85
57. McLeod HL, Siva C. The thiopurine S-methytranferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002;3(1):89-98
58. Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000;42(4):628-32
59. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361(9376):2235-42
60. Fertrin KY, Goncalves MS, Saad ST, Costa FF. Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet 2002;108(2):117-9
61. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998;95(14):8170-4
62. United States Food and Drug Administration. Camptosar label. Available from: http://www.fdagov/cder/foi/label/2005/020571s024,027,028iblpdf
63. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006;24(28):4534-8
64. Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99(17):1290-5
65. Baker SD, van Schaik RHN, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004;10(24):8341-50
66. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997;37(1 Suppl):S40-8
67. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10(3):187-216
68. Zaigler M, Tantcheva-Poor I, Fuhr U. Problems and perspectives of phenotyping fbr drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther 2000;38(1):1-9
69. Tanaka E, Kurata N, Yasuhara H. How usefid is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 2003; 28(3):157-65
70. Yamamoto N, Tamura T, Murakami H, et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005;23(6):1061-9
71. Van der Bol JM, Mathijssen RH, Verweij J, et al. CYP3A pheynotype-based individualized dosing of irnotecan to reduce interindividual variability in pharmacokinetics and toxicity: resutls from a randomized trial. 2008 ASCO Annual Meeting; 2008
72. Frye RF. Probing the world of cytochrome P450 enzymes. Mol Interv 2004;4(3):157-62
73. Gurney H. Developing a new framework for dose calculation. J Clin Oncol 2006;24(10):1489-90
74. Cooper R, Kaanders JH. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls. Eur J Cancer 2005;41(9):1261-6
75. Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin Pharmacokinet 1987;13(4):205-27
76. Graf N, Winkler K, Bedemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994;12(7):1443-51
77. Pearson AD, Amineddine HA, Yule M, et al. The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer 199164(1):169-73
78. Wolfrom C, Hepp R, Hartmann R, et al. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. Eur J Clin Pharmacol 1990;39(4):377-83
79. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008;26(13):2099-105
80. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002;16(4):253-62
81. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338(8):499-505
82. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10(4):520-8
83. Milano G, Roman P, Khater R, et al. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 1988;41(4):537-41
84. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989;59(2):287-90
85. Ranson MR, Scarffe JH. Population and Bayesian pharmacokinetics in oncology. Clin Oncol (R Coll Radiol) 1994;6(4):254-60
86. Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998;44(2):388-400
87. Kaestner SA, Sewell GJ. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol) 2007;19(1):23-37
88. Rivera E, Erder MH, Moore TD, et al. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model. Cancer 2003;98(2):222-8
89. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332(14):901-6
90. Gurney H, Dodwell D, Thatcher N, Tattersall MH. Escalating drug delivery in cancer chemotherapy: a review of concepts and practice - part 2. Ann Oncol 1993;4(2):103-15
91. Gurney H. I don't underdose my patients ... do I? Lancet Oncol 2005;6(9):637-8
92. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997;13(1):169-83
93. Desoize B, Robert J. Individual dose adaptation of anticancer drugs. Eur J Cancer 1994;30A(6):844-51
94. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26(13):2118-23
95. Chang AY. The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opin Investig Drugs 2008;17(3):401-11
96. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007;25(30):4707-13
97. Arbuck SG, Douglass HO, Crom WR, et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986;4(11):1690-5
98. Alexandre J, Rey E, Girre V, et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 2007;18(1):168-72
99. Twelves CJ, Dobbs NA, Michael Y, et al. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 1992;66(4):765-9
100. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996;14(1):257-67
101. Van den Bongard HJ, Mathot RA, Beijnen JH, Schellens JH. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000;39(5):345-67
102. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14(4):567-72
103. Maring JG, van Kaenburg AB, Haasjes J, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002;86(7):1028-33
104. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS 14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002;12(7):555-8
105. van Kuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+ 1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7(5):1149-53
106. Ando Y, Saka H, Ando M, et al. Polyrnorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60(24):6921-6
107. Chlebowski RT, Paroly WS, Pugh RP, et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980;64(1):47-51
108. Weiss AJ, Metter GE, Fletcher WS, et al. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976;60(7):813-22
109. Legha SS, Benjamin RS, MacKay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96(2):133-9
110. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorecral adenocarcinoma. Cancer 1975;36(1):123-8
111. Hande K, Messenger M, Wagner J, et al. Inter- and intrapatient variabHity in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 1999;5(10):2742-7
112. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97(1):30-9
113. Frye RF, Fitzgerald SM, Lagattuta TF, Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76(4):323-9
114. De Jong FA, Sparreboom A, Verweij J, Mathijssen RH. Likstyle habits as a contributor to anti-cancer treatment failure. Eur J Cancer 2008;44(3):374-82
115. Van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007;25(19):2719-26
116. Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6(4):1255-8
117. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20(17):3683-90
118. Robertson GR, Liddle C, Clarke SJ. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 2008;83(6):894-7
119. Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Chn Cancer Res 2005;11(20):7398-404
120. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 2002;12(3):251-63
121. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007;63(4):321-33
122. Frye RF, Matzke GR, Adedoyin A, et al. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997; 62(4):365-76
123. Wong M, Evans S, Rivory LP, et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 2005;77(1):33-42
124. Rivory LP, Slaviero K, Seale JP, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000;6(9):3480-5
125. Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974;291(19):998-1000
126. Poikonen P, Saarto T, Lundin J, et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80(11):1763-6
127. Saarto T, Blomqvist C, Rissanen P, et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997;75(2):301-5
128. Colleoni M, Price K, Castiglione-Gertsch M, et al. Dose-response effect of adjuvant cyclophosphamide, methontrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 1998;34(11):1693-700
129. Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005;6(9):669-77
130. Rankin EM, Mill L, Kaye SB, et al. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 1992;65(2):275-81